Lucid Diagnostics Inc

Lucid Diagnostics insider stake rise fuels optimism as breakthrough esophageal brush‑biopsy tech shows 92% sensitivity, 88% specificity, and strong FDA support, hinting at future growth.

Lucid Diagnostics insider buying spikes amid VA contract win—an insider confidence boost, but negative earnings and low valuations highlight the need for solid revenue and reimbursement wins to create lasting value.